Payment overview · 2025
General Payments
$367.12
20 reported records · 14 companies
Healthcare provider profile · identity verified
Christopher Brian Clayton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SCOTTSBORO, AL · NPI 1205154127
Verified facts
What the public records show
CMS Open Payments records show Christopher Brian Clayton, M.D. received $367.12 in general payments during 2025 across 20 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $73.91 | 20.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.19 | 12.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.87 | 8.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.89 | 7.9% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $24.32 | 6.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.04 | 6.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $22.00 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.55 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.82 | 5.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.24 | 5.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.26 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.10 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.14 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.79 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.12 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $73.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $10.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 345 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 121 |
| Gabapentin | Gabapentin | 335 | 82 |
| Tramadol Hcl | Tramadol Hcl | 319 | 87 |
| Omeprazole | Omeprazole | 300 | 92 |
| Losartan Potassium | Losartan Potassium | 254 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 57 |
| Lisinopril | Lisinopril | 202 | 67 |
| Prednisone | Prednisone | 184 | 126 |
| Metformin Hcl | Metformin Hcl | 177 | 60 |
| Ozempic | Semaglutide | 167 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 46 |
| Simvastatin | Simvastatin | 156 | 44 |
| Trazodone Hcl | Trazodone Hcl | 156 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 50 |
| Montelukast Sodium | Montelukast Sodium | 150 | 46 |
| Clonazepam | Clonazepam | 148 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 24 |
| Glipizide | Glipizide | 136 | 41 |
| Sertraline Hcl | Sertraline Hcl | 135 | 37 |
| Metformin Hcl Er | Metformin Hcl | 128 | 39 |
| Eliquis | Apixaban | 125 | 29 |
| Potassium Chloride | Potassium Chloride | 120 | 44 |
| Carvedilol | Carvedilol | 115 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 34 |
| Meloxicam | Meloxicam | 111 | 43 |
| Furosemide | Furosemide | 109 | 45 |
| Jardiance | Empagliflozin | 109 | 30 |
| Buspirone Hcl | Buspirone Hcl | 108 | 40 |
| Lorazepam | Lorazepam | 106 | 24 |
| Allopurinol | Allopurinol | 105 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 39 |
| Pregabalin | Pregabalin | 100 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 51 |
| Azithromycin | Azithromycin | 90 | 77 |
| Temazepam | Temazepam | 90 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 69 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 60 |
| Fluconazole | Fluconazole | 75 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 24 |
| Alprazolam | Alprazolam | 70 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 36 |
| Cefdinir | Cefdinir | 62 | 54 |
| Famotidine | Famotidine | 62 | 19 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 23 |
| Levofloxacin | Levofloxacin | 59 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 14 |
| Sucralfate | Sucralfate | 53 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 34 |
| Methocarbamol | Methocarbamol | 44 | 19 |
| Spironolactone | Spironolactone | 44 | 12 |
| Atenolol | Atenolol | 43 | 15 |
| Estradiol | Estradiol | 43 | 11 |
| Glimepiride | Glimepiride | 43 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 35 |
| Valsartan | Valsartan | 42 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 38 | 17 |
| Torsemide | Torsemide | 38 | 17 |
| Alendronate Sodium | Alendronate Sodium | 37 | 13 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 21 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Celecoxib | Celecoxib | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 18 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 18 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 14 |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 12 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 17 | 13 |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.12 · 20 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, FANAPT, JARDIANCE, JATENZO, Korlym, MONOFERRIC, NURTEC ODT, OTEZLA, Ozempic, RECORLEV, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error